

Geographic Atrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/G8DA7F15DFB2EN.html>

Date: May 2024

Pages: 131

Price: US\$ 6,499.00 (Single User License)

ID: G8DA7F15DFB2EN

Abstracts

The 7 major geographic atrophy markets reached a value of US\$ 24.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 44.5 Billion by 2034, exhibiting a growth rate (CAGR) of 5.7% during 2024-2034.

The geographic atrophy market has been comprehensively analyzed in IMARC's new report titled "Geographic Atrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Geographic atrophy is an advanced form of dry age-related macular degeneration that affects the retina, a part of the eye that sends information to the brain to enable sight. In this stage, the damage is so severe that it causes blind spots in the patient's central vision. A patient can have both wet and dry age-related macular degeneration simultaneously and develop geographic atrophy independently of having wet age-related macular degeneration. This disease leads to sharply demarcated atrophy of the outer retinal tissue, retinal pigment epithelium, and choriocapillaris. The common symptoms experienced by patients are central vision loss, difficulty in low-light conditions, and trouble seeing colors. Initially, the sign is identified while reading when one or several letters are missing from a word or when looking at faces, a small region of the face is not clearly visible. Over several years, geographic atrophy causes the central vision to diminish and the visual acuity comes down to 20/200. However, it does not usually affect peripheral vision. Geographic atrophy can be identified by an ophthalmologist using retinal imaging and a dilated examination. In a dilated exam, geographic atrophy appears as a patch of the retina without dark melanin pigment. Imaging techniques can also be used to detect geographic atrophy, including optical coherence tomography (OCT), retinal color photographs, autofluorescence imaging, etc.

The increasing prevalence of retinal disorders along with the expanding geriatric population is primarily driving the geographic atrophy market. Additionally, the rising incidences of obesity and cardiovascular diseases (CVDs) on account of changing dietary patterns, sedentary lifestyles, and unhealthy habits like smoking are further creating a positive outlook for the market. In line with this, the escalating usage of smartphones, laptops, televisions, etc., which is leading to prolonged and excessive screen time, is also propelling the market growth. Moreover, the introduction of retinal gene therapies, which involve injecting adeno-associated virus (AAV) into the body to prevent the development of abnormal blood vessels, is further acting as a significant growth-inducing factor. Besides this, the widespread adoption of autofluorescence imaging technology to visualize the retinal pigment epithelium (RPE) in order to assess the progression rate of the disease is also bolstering the global market. Additionally, several key players are making substantial investments in developing imaging technologies that will contribute to the understanding of the genesis and pathophysiological mechanisms of geographic atrophy. This, in turn, is positively influencing the market growth. Numerous other factors, such as extensive R&D activities for launching innovative and effective drugs and the increasing expenditure on healthcare to facilitate access to affordable treatment options, are expected to drive the geographic atrophy market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the geographic atrophy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for geographic atrophy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the geographic atrophy market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the geographic atrophy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the geographic atrophy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current geographic atrophy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance

Late-Stage Pipeline Drugs

Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the geographic atrophy market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the geographic atrophy market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the geographic atrophy market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the size of the geographic atrophy patient pool (?2018-2023?) across the seven major markets?

What would be the forecasted patient pool (?2024-2034?) across the seven major markets?

What are the key factors driving the epidemiological trend of geographic atrophy?

What will be the growth rate of patients across the seven major markets?

Geographic Atrophy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for geographic atrophy drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the geographic atrophy market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 GEOGRAPHIC ATROPHY - INTRODUCTION

- 4.1 Overview
- 4.2 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
- 4.3 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
- 4.4 Competitive Intelligence

5 GEOGRAPHIC ATROPHY - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 GEOGRAPHIC ATROPHY - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets

- 7.2.1 Epidemiology Scenario (?2018-2023?)
- 7.2.2 Epidemiology Forecast (?2024-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (?2018-2023?)
 - 7.3.2 Epidemiology Forecast (?2024-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (?2018-2023?)
 - 7.4.2 Epidemiology Forecast (?2024-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (?2018-2023?)
 - 7.5.2 Epidemiology Forecast (?2024-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (?2018-2023?)
 - 7.6.2 Epidemiology Forecast (?2024-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (?2018-2023?)
 - 7.7.2 Epidemiology Forecast (?2024-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (?2018-2023?)
 - 7.8.2 Epidemiology Forecast (?2024-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (?2018-2023?)
 - 7.9.2 Epidemiology Forecast (?2024-2034?)

8 GEOGRAPHIC ATROPHY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 GEOGRAPHIC ATROPHY - UNMET NEEDS

10 GEOGRAPHIC ATROPHY - KEY ENDPOINTS OF TREATMENT

11 GEOGRAPHIC ATROPHY - MARKETED PRODUCTS

- 11.1 List of Geographic Atrophy Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Drug Name - Company Name
 - 11.1.1.1 Drug Overview

- 11.1.1.2 Mechanism of Action
- 11.1.1.3 Regulatory Status
- 11.1.1.4 Clinical Trial Results
- 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 GEOGRAPHIC ATROPHY - PIPELINE DRUGS

12.1 List of Geographic Atrophy Pipeline Drugs Across the Top 7 Markets

12.1.1 Pegcetacoplan - Apellis Pharmaceuticals/Swedish Orphan Biovitrum

- 12.1.1.1 Drug Overview
- 12.1.1.2 Mechanism of Action
- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status

12.1.2 Avacincaptad Pegol - IVERIC bio

- 12.1.2.1 Drug Overview
- 12.1.2.2 Mechanism of Action
- 12.1.2.3 Clinical Trial Results
- 12.1.2.4 Safety and Efficacy
- 12.1.2.5 Regulatory Status

12.1.3 Metformin

- 12.1.3.1 Drug Overview
- 12.1.3.2 Mechanism of Action
- 12.1.3.3 Clinical Trial Results
- 12.1.3.4 Safety and Efficacy
- 12.1.3.5 Regulatory Status

12.1.4 Retinol deuterated - Alkeus Pharmaceuticals

- 12.1.4.1 Drug Overview
- 12.1.4.2 Mechanism of Action
- 12.1.4.3 Clinical Trial Results
- 12.1.4.4 Safety and Efficacy
- 12.1.4.5 Regulatory Status

12.1.5 Iptacopan - Novartis Pharmaceuticals

- 12.1.5.1 Drug Overview
- 12.1.5.2 Mechanism of Action
- 12.1.5.3 Clinical Trial Results
- 12.1.5.4 Safety and Efficacy
- 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report.

13. GEOGRAPHIC ATROPHY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14 GEOGRAPHIC ATROPHY - MARKET SCENARIO

14.1 Market Scenario - Key Insights

14.2 Market Scenario - Top 7 Markets

14.2.1 Geographic Atrophy - Market Size

14.2.1.1 Market Size (?2018-2023?)

14.2.1.2 Market Forecast (?2024-2034?)

14.2.2 Geographic Atrophy - Market Size by Therapies

14.2.2.1 Market Size by Therapies (?2018-2023?)

14.2.2.2 Market Forecast by Therapies (?2024-2034?)

14.3 Market Scenario - United States

14.3.1 Geographic Atrophy - Market Size

14.3.1.1 Market Size (?2018-2023?)

14.3.1.2 Market Forecast (?2024-2034?)

14.3.2 Geographic Atrophy - Market Size by Therapies

14.3.2.1 Market Size by Therapies (?2018-2023?)

14.3.2.2 Market Forecast by Therapies (?2024-2034?)

14.3.3 Geographic Atrophy - Access and Reimbursement Overview

14.4 Market Scenario - Germany

14.4.1 Geographic Atrophy - Market Size

14.4.1.1 Market Size (?2018-2023?)

14.4.1.2 Market Forecast (?2024-2034?)

14.4.2 Geographic Atrophy - Market Size by Therapies

14.4.2.1 Market Size by Therapies (?2018-2023?)

14.4.2.2 Market Forecast by Therapies (?2024-2034?)

14.4.3 Geographic Atrophy - Access and Reimbursement Overview

14.5 Market Scenario - France

14.5.1 Geographic Atrophy - Market Size

14.5.1.1 Market Size (?2018-2023?)

14.5.1.2 Market Forecast (?2024-2034?)

14.5.2 Geographic Atrophy - Market Size by Therapies

14.5.2.1 Market Size by Therapies (?2018-2023?)

14.5.2.2 Market Forecast by Therapies (?2024-2034?)

- 14.5.3 Geographic Atrophy - Access and Reimbursement Overview
- 14.6 Market Scenario - United Kingdom
 - 14.6.1 Geographic Atrophy - Market Size
 - 14.6.1.1 Market Size (?2018-2023?)
 - 14.6.1.2 Market Forecast (?2024-2034?)
 - 14.6.2 Geographic Atrophy - Market Size by Therapies
 - 14.6.2.1 Market Size by Therapies (?2018-2023?)
 - 14.6.2.2 Market Forecast by Therapies (?2024-2034?)
 - 14.6.3 Geographic Atrophy - Access and Reimbursement Overview
- 14.7 Market Scenario - Italy
 - 14.7.1 Geographic Atrophy - Market Size
 - 14.7.1.1 Market Size (?2018-2023?)
 - 14.7.1.2 Market Forecast (?2024-2034?)
 - 14.7.2 Geographic Atrophy - Market Size by Therapies
 - 14.7.2.1 Market Size by Therapies (?2018-2023?)
 - 14.7.2.2 Market Forecast by Therapies (?2024-2034?)
 - 14.7.3 Geographic Atrophy - Access and Reimbursement Overview
- 14.8 Market Scenario - Spain
 - 14.8.1 Geographic Atrophy - Market Size
 - 14.8.1.1 Market Size (?2018-2023?)
 - 14.8.1.2 Market Forecast (?2024-2034?)
 - 14.8.2 Geographic Atrophy - Market Size by Therapies
 - 14.8.2.1 Market Size by Therapies (?2018-2023?)
 - 14.8.2.2 Market Forecast by Therapies (?2024-2034?)
 - 14.8.3 Geographic Atrophy - Access and Reimbursement Overview
- 14.9 Market Scenario - Japan
 - 14.9.1 Geographic Atrophy - Market Size
 - 14.9.1.1 Market Size (?2018-2023?)
 - 14.9.1.2 Market Forecast (?2024-2034?)
 - 14.9.2 Geographic Atrophy - Market Size by Therapies
 - 14.9.2.1 Market Size by Therapies (?2018-2023?)
 - 14.9.2.2 Market Forecast by Therapies (?2024-2034?)
 - 14.9.3 Geographic Atrophy - Access and Reimbursement Overview

15 GEOGRAPHIC ATROPHY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

16 GEOGRAPHIC ATROPHY MARKET - SWOT ANALYSIS

16.1 Strengths

16.2 Weaknesses

16.3 Opportunities

16.4 Threats

17 APPENDIX

I would like to order

Product name: Geographic Atrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/G8DA7F15DFB2EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8DA7F15DFB2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

